H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 35.1 DKK 0.57% Market Closed
Market Cap: 35B DKK

Operating Margin
H Lundbeck A/S

25.6%
Current
21%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
25.6%
=
Operating Profit
6.2B
/
Revenue
24.1B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DK
H Lundbeck A/S
CSE:HLUN A
34.8B DKK
26%
US
Eli Lilly and Co
NYSE:LLY
971.9B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
509.1B USD
27%
CH
Roche Holding AG
SIX:ROG
252.3B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP
24%
CH
Novartis AG
SIX:NOVN
202.4B CHF
33%
US
Merck & Co Inc
NYSE:MRK
249.5B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
147B USD
29%
No Stocks Found

H Lundbeck A/S
Glance View

Market Cap
34.8B DKK
Industry
Pharmaceuticals

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

HLUN A Intrinsic Value
57.34 DKK
Undervaluation 39%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
25.6%
=
Operating Profit
6.2B
/
Revenue
24.1B
What is the Operating Margin of H Lundbeck A/S?

Based on H Lundbeck A/S's most recent financial statements, the company has Operating Margin of 25.6%.

Back to Top